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Objectives: The aim of this study was to compare the long-term effectiveness of subthalamic nucleus
deep brain stimulation (STN-DBS) between patients with young-onset Parkinson’s disease (YOPD) and
late-onset Parkinson’s disease (LOPD).
Materials and Methods: Twenty-one YOPD patients with a mean age at onset of 32.8  6.9 years and
another 69 LOPD patients with a mean age at onset of 53.2  6.9 years undergoing STN-DBS were fol-
lowed. The mean durations of follow-up for those who were followed for more than 3 years were
57.22  14.54 months in the YOPD group and 46.77  13.84 months in the late onset group.
Results: Motor disabilities and activities of daily living in patients with LOPD and YOPD signiﬁcantly
improved after the operation. However, YOPD patients showed signiﬁcantly less improvement in Uniﬁed
Parkinson’s Disease Rating Scale Part II (p ¼ 0.001) and Part III (p ¼ 0.031), rigidity (p ¼ 0.033), and axial
(p ¼ 0.046) scores than late onset patients more than 3 years after surgery. YOPD patients had higher
scores for rigidity (p ¼ 0.007) and bradykinesia (p ¼ 0.044) than LOPD patients at the ﬁnal post-surgery
follow-up. Late onset PD patients had more postoperative hypophonia, whereas EOPD patients displayed
more stimulation dyskinesia. The effects of STN-DBS on psychiatric complications and cerebral bleeding
were similar in both groups.
Conclusion: YOPD patients and LOPD patients had similar beneﬁts and risks from medication-related
complications with STN-DBS. The YOPD group had relatively less improvement from acute deep brain
stimulation than the LOPD group during long-term follow-up, which could possibly be explained by
different disease evolutions and underlying pathophysiology in these two groups.
Copyright  2012, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Young-onset Parkinson’s disease (YOPD) is arbitrarily deﬁned as
an onset of symptoms between ages 21 and 40 years [1]. Although
these patients seem to experiencemotor symptoms similar to those
of patients with late-onset Parkinson’s disease (LOPD), earlier
motor ﬂuctuation and dyskinesia with slower progression of motor
features have been noted chronologically. In addition to its great
impact on the everyday, occupational, and social functioning ofry, Buddhist Tzu Chi General
lien, Taiwan. Tel.: þ886 3
Y. Chen).
ddhist Compassion Relief Tzu Chipatients, YOPD is also characterized by several neuropsychological
features [2,3]. Researchers have discussed the similar frequency of
psychiatric diseases in patients with YOPD and LOPD, and sug-
gested that psychosocial issues deserve more attention in YOPD
patients [4,5].
The long-term effectiveness of subthalamic nucleus deep brain
stimulation (STN-DBS) has been reported in patients with PD [6].
Differences in the evolution of disease between different patient
groups may inﬂuence the impact of STN-DBS on quality of life, even
though these patient groups may all display similar responses to
levodopa treatment preoperatively [7]. Although previous studies
have recommended STN-DBS over internal globus pallidus deep
brain stimulation (GPi-DBS) for YOPD patients, comparison of the
long-term results of STN-DBS between patients with YOPD and
LOPD has not been addressed [8].Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
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debate. While positron emission tomography studies have revealed
progressive degeneration of dopaminergic neurons upon STN
modulation, animal studies demonstrated a neuroprotective effect
from STN modulation [9,10]. Levodopa responsiveness deteriorates
during long-term follow-up, which may be a result of disease
progression or of a direct stimulation effect [11]. It is uncertain
whether STN-DBS is neuroprotective for YOPD patients and this
effect needs to be conﬁrmed.
To illustrate the long-term beneﬁts and impact of STN-DBS for
YOPD patients, we compared DBS effectiveness and adverse effects
between patients with YOPD and LOPD. Short-term and long-term
follow-up of disease progression and evolution relative to preop-
erative characteristics was carried out.2. Materials and methods
2.1. Patients
A total of 90 consecutive parkinsonian patients underwent
bilateral STN-DBS performed by the operative team at Department
of Neurosurgery Tzu Chi General Hospital, Taiwan, between
February 2003 andMay 2010. The diagnosis of PD conformed to the
diagnostic criteria of the United Kingdom PD Society Brain Bank.
There were 21 patients in the YOPD group (disease onset between
ages 21 and 40 years) and the other 69 patients had typical PD
(LOPD) group. The inclusion criteria were as follows: (1) good
levodopa response on the Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS) Part III (>30%); (2) drug-related complications (e.g.,
dyskinesia, and “on-off phenomenon”) even under optimal anti-
parkinsonian medication adjustment; (3) no structural lesions on
brain magnetic resonance imaging (MRI); and (4) absence of
dementia. All patients participating in this study signed informed
consents for STN-DBS surgery and the procedures involved in the
study. The evaluation procedures in the studywere carried out with
the ethical approval of our institutional review board (Tzu Chi
General Hospital, Hualien, Taiwan).2.2. Surgical procedure
A Leksell G frame was used for the stereotactic procedure.
Images for targeting were obtained from a 1.5-Tesla MRI unit
(General Electric, Milwaukee, WI, USA). The standard settings
included T1-weighted axial images (TR: 26 ms, TE: 6.9 ms, matrix
size: 256 x 192, thickness: 0.7 mm) and T2-weighted axial images
(TR: 4800ms, TE: 95ms, matrix size: 256 x 192, thickness: 2.0mm).
Each of these sequences was performed in contiguous slices. The
images were transferred to a database (Digital Image Communi-
cations in Medicine) through the picture archiving and communi-
cation system on a neuronavigation workstation (BrainLab
VectorVision, Westchester, IL, USA). T1 images were used for the
identiﬁcation and measurement of the anterior commissure and
posterior commissure length in both groups. The tentative surgical
target coordinates for the tip of the permanent implantable elec-
trode were set at the central lowest border of the STN, the inter-
section point between the line of the anterior border and 2 mm
lateral of the red nucleus on T2 images. The quadripolar DBS elec-
trodes (Model 3389; Medtronic, Englewood, CO, USA) were
implanted after microelectrode recording and test stimulation
procedures. After 1 week, the electrode cables were connected to
an implantable pulse generator (Kinetra; Medtronic, Minneapolis,
MN, USA). The same surgical team performed all of the surgical
procedures, which have been described in detail in our previous
study [12]. An acute stimulation test was performed 1 week aftersurgery to select the optimal stimulation contact and parameters
for chronic stimulation.
2.3. Clinical evaluation
Mentation, behavior and mood, activities of daily living, motor
examination, and levodopa-related motor complications (UPDRS
Parts I, II, III, and IV) were evaluated 1 month prior to surgery and 3,
12, 24, 36, 48, 60, and 72 months after surgery. We included
patients with different durations of follow-up in order to collect all
the data up to more than 3 years of follow-up. The preoperative
characteristics did not show signiﬁcant differences between groups
except for age at disease onset and UPDRS Part IV scores. The
“medication (MED) off” status for the motor examination was
evaluated at least 12 hours after the withdrawal of dopaminergic
medication as deﬁned by the Core Assessment Program for Surgical
Interventional Therapy in Parkinson’s Disease [13]. The magnitude
of levodopa response in “MED on” was assessed after administra-
tion of a dose of levodopa/benserazide (Roche Products, Basel,
Switzerland) equivalent to the usual morning and effective dose of
dopaminergic treatment. The bradykinesia scores included Items
23e26 and 31 of UPDRS Part III. The axial score evaluation included
speech, rising from a chair, gait, and postural instability (Items 18
and 27e30 of UPDRS Part III). All patients were evaluated post-
operatively in 4 conditions: (1) “stimulation (DBS) off” and “MED
off”, after the DBS was switched off for at least 2 hours and with no
dopaminergic treatment for 12 hours; (2) “DBS on” and “MED off”,
after stimulationwas switched on for at least 2 hours; (3) “DBS off”
and “MED on”; and (4) “DBS on” and “MED on”. We also followed
Schwab and England Activities of Daily Living Scale (SEADL) and
mini-mental state examination (MMSE) between groups.
The dosage of antiparkinsonian medication was expressed as
the levodopa equivalent daily dosage (LEDD) with the sum of the
dose of regular levodopa-benserazide (or levodopa-carbidopa),
plus 0.75 times the dose of controlled-release levodopa benser-
azide (or levodopa-carbidopa), plus 10 times the dose of bromo-
criptine, plus 25 times the dose of ropinirole. In patients taking
entacapone, the sum of regular levodopa and 0.75 times the dose of
controlled-release levodopa was multiplied by a factor of 1.25 [14].
2.4. Statistical analysis
For preoperative characteristics, means of normally distributed
variables were compared using the independent-samples t test and
nonnormally distributed variables were assessed with Mann-
Whitney tests. To analyze the data from the preoperative period
to 3, 6, 12, 24, and >36 months after surgery, comparisons of the
acute DBS effect (in “MED off”) on UPDRS scores, baseline UPDRS
scores (in “DBS off”/“MED off”) Hoehn and Yahr (H&Y) staging, and
the LEDD between groups (YOPD vs LOPD) were conducted with
the independent-samples t test. Repeated measures of analyses of
variance were performed for serial follow-up of stimulation
parameters and MMSE between groups.
Adverse effects were compared using the Wilcoxon matched-
pairs signed rank sum test. A p value of <0.05 was considered
signiﬁcant. Statistical analyses were performed using SPSS software
(SPSS, Chicago, IL, USA).
3. Results
There were 21 YOPD patients with a mean age at disease onset
of 32.8  6.9 years and 69 LOPD patients with a mean age at onset
of 53.2  6.9 years. YOPD patients had similar levels of levodopa
responsiveness in UPDRS Parts I, II, and III scores compared with
patients with LOPD. However, YOPD patients exhibitedmore severe
S.-T. Tsai et al. / Tzu Chi Medical Journal 24 (2012) 65e72 67drug-related dyskinesia in Part IV. There were no differences in
disease severity in “MED off” H&Y stage, SEADL scores and LEDD
(Table 1).
Similar to previous long-term studies, the UPDRS Parts II, III, and
IV all improved signiﬁcantly in both groups postoperatively (Fig. 1).
The intergroup comparison showed signiﬁcant differences at more
than 3 years follow-up, when YOPD patients showed a reduced
response to DBS in Part II (p¼ 0.001) and Part III (p¼ 0.031). Further
analysis of cardinal motor symptoms (tremor, rigidity, bradyki-
nesia, and axial scores) demonstrated that the effect of DBS on
rigidity and axial scores in YOPD patients was signiﬁcantly less than
in LOPD patients (p ¼ 0.033 and p ¼ 0.046, respectively).
In terms of disease progression and evolution, both groups were
analyzed from preoperative “MED off” to postoperative “DBS off”/
“MED off” status. There were no signiﬁcant differences from UPDRS
Parts I, II, and III scores to H&Y staging with the exception of an
increased deterioration in rigidity scores (p ¼ 0.007) and bradyki-
nesia (p¼ 0.044) in YOPD patients during the 3-year follow-up. The
within-group analysis did not show any signiﬁcant difference in
disease progression (Fig. 2).
The LEDD signiﬁcantly decreased after the operation and
remained stable up to the 3-year follow-up in both groups (YOPD
vs. LOPD; 54.9% vs. 52.24% at 3 months, 53.83% vs. 51.85% at 1 year,Table 1
Preoperative clinical characteristics of young-onset (YOPD) and late-onset Parkinson’s di
Sex, no. of patients YOPD (n ¼ 21)
Male/Female 17.0/4.0
Disease onset age (y) 32.8  6.9
Age at STN-DBS (y) 44.6  10.1
Duration of the disease (y) 11.9  7.3
Number of patients and mean duration of follow-up (mo)
Number Duration
3 mo 1 3
6 mo 2 7  1.41
12 mo 1 12
24 mo 8 25.63  4.
>36 mo 9 57.22  14
Lost from follow-up 0
UPDRS Part I "off" 3.9  3.2
UPDRS Part I "on" 2.9  3.4
UPDRS Part I improvement, % 32.2  36.4
UPDRS Part II "off" 22.0  9.5
UPDRS Part II "on" 10.6  7.5
UPDRS Part II improvement, % 49.9  22.9
UPDRS Part III "off" 49.6  12.5
UPDRS Part III "on" 26.3  12.5
UPDRS Part III improvement, % 48.2  16.1
Tremor "off" 7.0  4.6
Tremor "on" 1.5  2.5
Tremor improvement, % 66.5  49.2
Rigidity "off" 11.6  4.3
Rigidity "on" 6.0  3.4
Rigidity improvement, % 48.0  21.3
Posture & Gait "off" 4.4  1.8
Posture & Gait "on" 2.4  1.7
Posture & Gait improvement, % 46.2  29.9
Axial "off" 9.5  4.0
Axial "on" 5.6  3.6
Axial improvement, % 41.1  26.6
UPDRS Part IV 7.2  3.7
Hoehn & Yahr stage "off" 3.6  0.9
Hoehn & Yahr stage "on" 2.5  0.7
SEADL score "off" 70.5  30.1
SEADL score "on" 86.7  21.8
LEDD, mg/day 789.7  355.9
Values are expressed as means  standard deviation.
* p < 0.05, ** p < 0.01.
LEDD: levodopa equivalent daily dosage; SEADL: Schwab and England Activities of Daily L
disease Rating Scale.60.78% vs. 42.28% at 2 years, 34.62% vs. 41.81% at >3 years follow-
up). Nevertheless, intergroup differences showed a trend at the
2-year follow-up (p¼ 0.085), with a lower LEDD in the YOPD group
than the LOPD group. The stimulation parameters also did not show
a signiﬁcant difference between groups (Table 2). Following serial
cognitive function evaluation with the MMSE, it was determined
that STN-DBS did not cause memory decline in either group
(Table 3).
In terms of complications, the LOPD group showed signiﬁcantly
more stimulation-related hypophonia, whereas the YOPD patients
displayed more stimulation dyskinesia. There were no differences
in postoperative psychiatric morbidity, such as depression or
hypomania, between groups. Both groups showed similar risks in
relation to debilitating intracerebral hemorrhage, malpositioned
leads and infection (Table 4).
4. Discussion
Our study conﬁrms the long-term effectiveness and safety of
STN-DBS for YOPD patients. Although patients with YOPD did not
differ signiﬁcantly from those with LOPD in respect to disease
severity and levodopa responsiveness, they showed fewer beneﬁts
on the UPDRS Parts II and III during long-term follow-up. Thesease (LOPD) patients.
LOPD (n ¼ 69) p value
42.0/27.0 0.0919
53.2  6.9 <0.0001**
62.9  7.1 <0.0001**
9.5  4.3 0.0679
Number Duration
3 3.33  0.58
7 6.86  1.07
17 13.47  2.43
00 11 25.36  3.14
.54 26 46.77  13.84
5
4.6  2.5 0.2782
3.6  2.3 0.2355
20.6  26.7 0.1857
20.8  9.3 0.5947
12.5  8.1 0.3342
39.1  27.0 0.1031
45.8  15.5 0.3006
27.4  13.2 0.7414
40.9  17.2 0.0842
6.0  5.4 0.4033
2.1  3.5 0.4598
58.1  40.9 0.4331
9.6  3.9 0.0590
5.4  3.6 0.5144
47.4  25.5 0.9206
4.1  1.7 0.4552
2.6  1.4 0.7115
36.7  26.0 0.1603
9.4  4.0 0.9253
6.3  3.0 0.4125
31.8  19.6 0.0854
5.0  3.8 0.0180*
3.3  0.8 0.0757
2.7  0.7 0.2610
73.5  25.1 0.6486
87.2  19.4 0.9189
785.0  374.4 0.9600
iving Scale; STN-DBS: subthalamic deep brain stimulation, UPDRS: Uniﬁed Parkinson
Fig. 1. The effect of acute deep brain stimulation (DBS) on the Uniﬁed Parkinson Disease Rating Scale (UPDRS; Parts I, II, III, and IV), tremor, rigidity, bradykinesia and axial scores
between patients with young onset Parkinson’s disease (YOPD; open bars) and late-onset Parkinson’s Disease (PDPD; black bars) 3 months, 1 year, 2 years and >3 years post-
operatively. The YOPD group had signiﬁcantly reduced beneﬁts on the UPDRS Parts II and III, rigidity, and axial scores from DBS compared with the LOPD group at >3 years follow-
up (* p < 0.05, ** p < 0.01). Data are presented as means  standard deviation.
S.-T. Tsai et al. / Tzu Chi Medical Journal 24 (2012) 65e7268LEDD also showed remarkable reduction in both groups post-
surgery and there were similar trends in stimulation parameters
during follow-up.Because of the inclusion criteria for STN-DBS, the preoperative
characteristics between YOPD and LOPD patients did not show
signiﬁcant differences in disease severity except for the time of
Fig. 2. Time course evolution of baseline scores on the Uniﬁed Parkinson Disease Rating Scale (UPDRS; Parts I, II, and III), Hoehn and Yahr staging (H&Y), tremor, rigidity, bra-
dykinesia, and axial scores between patients with young onset Parkinson’s disease (YOPD; open circles) and late-onset Parkinson’s disease (LOPD; black squares) from preoperative
medication off to stimulation off and medication off 3 months, 1 year, 2 years and >3 years postoperatively. The YOPD group had signiﬁcantly* higher scores in rigidity and
bradykinesia than LOPD patients at more than 3 years follow-up (* p < 0.05, ** p < 0.01).
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Table 2
Stimulation parameters in young-onset (YOPD) and late-onset Parkinson’s disease (LOPD) patients.
3 months 6 months 12 months 24 months p
Right side Left side Right side Left side Right side Left side Right side Left side Right side Lt side
Voltage (V)
YOPD 2.7  0.7 2.9  0.5 3.0  0.6 3.2  0.5 3.2  0.6 3.3  0.4 3.4  0.5 3.4  0.7 0.2975 0.8874
LOPD 2.9  0.4 2.9  0.6 3.1  0.4 2.9  0.7 3.4  0.5 3.1  0.8 3.3  0.4 3.2  0.4
Frequency (Hz)
YOPD 145  19 143  18 148  21 146  21 150  24 150  23 147  18 150  18 0.9632 0.9648
LOPD 145  16 141  26 148  17 148  17 149  17 148  17 150  20 149  20
Pulse width (mS)
YOPD 62  7 60  0 64  11 64  11 66  13 66  12 62  8 69  14 0.5219 0.3521
LOPD 61  5 61  5 62  7 61  5 63  9 61  6 64  11 64  11
S.-T. Tsai et al. / Tzu Chi Medical Journal 24 (2012) 65e7270disease onset and higher Part IV scores in the YOPD group. The
levodopa responsiveness was also similar between groups. These
results are consistent with previous reports showing that YOPD
patients develop earlier and have more severe levodopa-induced
dyskinesia and motor ﬂuctuation [15] than LOPD patients.
Young-onset parkinsonism occurs in 3% to 5% of all patients with
parkinsonism but this is as high as 10% in Japan [1]. Of the 90
patients undergoing STN-DBS surgery, 23% had YOPD. These
patients had a higher incidence of medication-related complica-
tions, which explains the necessity for STN-DBS in Asian pop-
ulations such as in Taiwan. In one study, nearly all YOPD patients
developed levodopa-related ﬂuctuation and dyskinesia after
a mean disease duration of 10 years or more [16]. Furthermore, the
higher male predominance of 4:1 in our YOPD group undergoing
STN-DBS might also explain the ethnic variability [7,8].
STN-DBS induced signiﬁcant improvements in UPDRS Part III by
54.77% in YOPD patients and 50.16% in LOPD patients at the 3-
month follow-up. These results were similar to previously repor-
ted short-term beneﬁts from STN-DBS in YOPD patients [8].
In the activities of daily life (UPDRS part II scores), the YOPD
group showed an even greater improvement with STN-DBS
(61.85%) vs. a 41.26% improvement in the late-onset PD patients.
Therefore, the magnitude of the preoperative levodopa response
could also predict the short-term beneﬁts of STN-DBS in YOPD
patients [11]. During long-term follow-up, the effectiveness of STN-
DBS seemed to decline in YOPD patients, such that UPDRS Part II
showed only a 25.95% improvement in YOPD patients, which was
less than the 45.37% improvement observed in LOPD patients;
UPDRS Part III only improved 31.46% in YOPD patients, compared
with 53.27% observed in LOPD patients. Phenotypic homogeneity
has clustered YOPD as a speciﬁc manifestation of PD [17]. Our study
echoed this observation after a long-term follow-up, which indi-
rectly indicates that the speciﬁc phenotype and entity of YOPD are
different from that of general idiopathic parkinsonism.
Most previous studies have reported slower disease progression
in YOPD with medical treatment than in LOPD [18]. The annual
progression and evolution after STN-DBS in our study showed
different trends of disease evolution between YOPD and LOPD
patients. The YOPD group showed signiﬁcantly higher scores in
rigidity and bradykinesia than the late onset group at the 3-year
follow-up. This might at least partially explain the more rapid
deterioration of acute STN-DBS effects in YOPD patients and also
indicates the development of underlying neuropathologicalTable 3
Cognitive evaluation with mini-mental state exam between young-onset (YOPD) and lat
Pre-operative 3 months 6 months
YOPD 28.2  1.9 28.0  1.3 28.7  1.7
LOPD 26.0  4.7 27.7  2.7 25.6  6.2changes after neuromodulation that depends on the patient’s age at
disease onset [19]. Comparing preoperative “MED off” to post-
operative “DBS off”/“MED off”, motor function did not worsen in
LOPD, indirectly supporting the neuroprotective effect of STN-DBS
[20,21]. Although motor disability was similar in the 2 groups
before surgery, YOPD patients displayed a trend towards longer
disease duration before surgery in our study, which was probably
because of slower progression. Future study should clarify whether
this group of patients would beneﬁt from STN-DBS in earlier stages
of the disease [22].
The LEDD was signiﬁcantly reduced and remained constant in
both groups. This could explain the improvement in motor function
in addition to the STN-DBS effects [23]. At the 2-year follow-up, the
LEDD in the YOPD group seemed to be less than in the LOPD group.
Four out of 13 patients were free from anti-parkinsonian medica-
tion after surgery. This might be due to the more restricted
nigrostriatal dopaminergic deﬁcit in YOPD patients and may
account for the delayed onset of impairment of cognition, sug-
gesting the possibility of DBS fully substituting for medication
[16,24].
Hypophonia occurred more often in LOPD patients than YOPD
patients, possibly because the LOPD groupwas older than the YOPD
group. However, stimulation-related impairment of speech should
be considered during long-term follow-up [25,26]. The YOPD group
developed more stimulation-related dyskinesia. Although the
provocation of dyskinesia with stimulation either during surgery or
the early postoperative programming period predicts the long-
term beneﬁts from STN-DBS, the motor improvement might be
offset by disabling dyskinesia [27,28]. The interaction between
subthalamic and pallidal activity is suggested to play a major role in
the pathogenesis of dyskinesia. The amelioration of stimulation-
related dyskinesia through proximal contact (stimulating sub-
thalamic ﬁbers) in previous reports and our YOPD patients suggests
possible beneﬁcial effects from GPi-DBS [28e30]. Previous studies
have shown the superiority of STN-DBS over GPi-DBS for YOPD
patients after 6 months, but a recent large, randomized trial
showed similar improvement after either pallidal or subthalamic
stimulation for 24 months [8,31]. Given the early development of
medication-related complications, lower medication requirements
and concerns regarding stimulation-related psychiatric effects, GPi-
DBS might be a good alternative for YOPD patients.
In this report, YOPD patients did not show signiﬁcantly more
psychiatric complications, such as depression and hypomania, thane-onset Parkinson’s disease (LOPD).
12 months 24 months >36 months p
27.3  2.3 26.9  3.8 27.4  2.8 0.7064
27.4  2.9 24.2  5.5 26.5  3.8
Table 4
Adverse effects with subthalamic nucleus deep brain stimulation in young-onset






n % n %
Adverse effects related to stimulation
Hypophonia 1 4.8 17 24.6 0.0470*
Eyelid apraxia 0 0.0 2 2.9 0.4358
Increased libido 3 14.3 2 2.9 0.0470*
Sialorrhea 2 9.5 11 15.9 0.4694
Decreased memory 1 4.8 12 17.4 0.1528
Dystonia 1 4.8 0 0.0 0.0696
Dyskinesias 8 38.1 7 10.1 0.0020**
Dysarthria 2 9.5 13 18.8 0.3213
General neurological and surgical complications
Depression 0 0.0 5 7.2 0.2087
Hypomania 2 9.5 8 11.6 0.7943
Perioperative confusion 1 4.8 7 10.1 0.4535
Weight gain 7 33.3 20 29.0 0.7073
Seizures 1 4.8 0 0.0 0.0696
Intracerebral hemorrhage 0 0.0 3 4.3 0.3366
Malpositioned leads 1 4.8 3 4.3 0.9366
Infections of the hardware 0 0.0 1 1.4 0.5840
Required removal of the system 0 0.0 1 1.4 0.5840
Battery failure 1 4.8 1 1.4 0.3729
IPG migration 0 0.0 1 1.4 0.5840
Wire revision 1 4.8 5 7.2 0.6934
* p < 0.05, ** p < 0.01.
S.-T. Tsai et al. / Tzu Chi Medical Journal 24 (2012) 65e72 71LOPD patients after STN-DBS. However, two patients without prior
psychiatric history in the YOPD group developed dopamine dys-
regulation syndrome and impulse control disorder after STN-DBS,
which have been reported in previous studies with contradictory
results [32,33]. Chronic dopamine stimulation in PD has been
associated with dyskinesia and increased impulsivity, which
provides further evidence that the basal ganglia is an organized
circuit for the selection and facilitation of motor and nonmotor
effects, which is especially true for YOPD [34,35]. Cerebral bleeding,
which is probably themost devastatingmorbidity and an inevitable
risk in DBS surgery, would have a lifelong impact on YOPD patients
[36]. Fortunately, this did not occur in our YOPD group, but this
issue still needs to be clariﬁed and the importance of associated
factors such as age should be assessed [37].
Our study showed the long-term beneﬁts of STN-DBS for both
YOPD and LOPD patients. Except for more stimulation-related
dyskinesia, YOPD patients did not have signiﬁcant differences in
adverse effects from LOPD patients. However, the possibility that
patients with advanced YOPD receive fewer beneﬁts from STN-DBS
than LOPD patients during long-term follow-up, as shown in our
study, deserves attention. A well-designed study with more
patients might shed light on the disease evolution for this speciﬁc
group of patients after surgery.References
[1] Golbe LI. Young-onset Parkinson’s disease: a clinical review. Neurology 1991;
41:168e73.
[2] Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Young- versus older-
onset Parkinson’s disease: impact of disease and psychosocial consequences.
Mov Disord 2003;18:1250e6.
[3] Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of
early-onset parkinsonism. Lancet Neurol 2006;5:355e63.
[4] Calne SM, Lidstone SC, Kumar A. Psychosocial issues in young-onset parkin-
son’s disease: current research and challenges. Parkinsonism Relat Disord
2008;14:143e50.
[5] Kummer A, Cardoso F, Teixeira AL. Frequency of psychiatric disorders in
young-onset Parkinson’s disease does not differ from typical-onset Parkin-
son’s disease. Parkinsonism Relat Disord 2009;15:153e5.[6] Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schüpbach M, et al.
A multicentre study on suicide outcomes following subthalamic stimulation
for Parkinson’s disease. Brain 2008;131:2720e8.
[7] Derost PP, Ouchchane L, Morand D, Ulla M, Llorca PM, Barget M, et al. Is DBS-
STN appropriate to treat severe Parkinson disease in an elderly population?
Neurology 2007;68:1345e55.
[8] Krack P, Pollak P, Limousin P, Hoffmann D, Xie J, Benazzouz A, et al. Sub-
thalamic nucleus or internal pallidal stimulation in young onset Parkinson’s
disease. Brain 1998;121:451e7.
[9] Hilker R, Portman AT, Voges J, Staal MJ, Burghaus L, van Laar T, et al. Disease
progression continues in patients with advanced Parkinson’s disease and
effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry
2005;76:1217e21.
[10] Wallace BA, Ashkan K, Heise CE, Foote KD, Torres N, Mitrofanis J, et al. Survival
of midbrain dopaminergic cells after lesion or deep brain stimulation of the
subthalamic nucleus in MPTP-treated monkeys. Brain 2007;130:2129e45.
[11] Piboolnurak P, Lang AE, Lozano AM, Miyasaki JM, Saint-Cyr JA, Poon YY, et al.
Levodopa response in long-term bilateral subthalamic stimulation for Par-
kinson’s disease. Mov Disord 2007;22:990e7.
[12] Lin SH, Chen TY, Lin SZ, Shyr MH, Chou YC, Hsieh WA, et al. Subthalamic deep
brain stimulation after anesthetic inhalation in Parkinson disease: a prelimi-
nary study. J Neurosurg 2008;109:238e44.
[13] Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, et al. Core
assessment program for intracerebral transplantations (CAPIT). Mov Disord
1992;7:2e13.
[14] Fine J, Duff J, Chen R, Chir B, Hutchison W, Lozano AM, et al. Long-term follow-
up of unilateral pallidotomy in advanced Parkinson’s disease. N Engl J Med
2000;342:1708e14.
[15] Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-
induced dyskinesias and response ﬂuctuations in young-onset Parkinson’s
disease. Neurology 1991;41:202e5.
[16] Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Par-
kinson’s disease revisitedeclinical features, natural history, and mortality.
Mov Disord 1998;13:885e94.
[17] Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA.
Heterogeneity of Parkinson’s disease in the early clinical stages using a data
driven approach. J Neurol Neurosurg Psychiatry 2005;76:343e8.
[18] Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor
impairment and disability in Parkinson disease: A population-based study.
Neurology 2005;65:1436e41.
[19] Zaidel A, Arkadir D, Israel Z, Bergman H. Akineto-rigid vs. tremor syndromes
in parkinsonism. Curr Opin Neurol 2009;22:387e93.
[20] Maesawa S, Kaneoke Y, Kajita Y, Usui N, Misawa N, Nakayama A, et al. Long-
term stimulation of the subthalamic nucleus in hemiparkinsonian rats: Neu-
roprotection of dopaminergic neurons. J Neurosurg 2004;100:679e87.
[21] Ostergaard K, Aa Sunde N. Evolution of Parkinson’s disease during 4 years of
bilateral deep brain stimulation of the subthalamic nucleus. Mov Disord 2006;
21:624e31.
[22] Schüpbach WM, Maltête D, Houeto JL, du Montcel ST, Mallet L, Welter ML,
et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized,
controlled trial. Neurology 2007;68:267e71.
[23] Nutt JG, Rufener SL, Carter JH, Anderson VC, Pahwa R, Hammerstad JP, et al.
Interactions between deep brain stimulation and levodopa in Parkinson’s
disease. Neurology 2001;57:1835e42.
[24] Giovannini P, Piccolo I, Genitrini S, Soliveri P, Girotti F, Geminiani G, et al.
Early-onset Parkinson’s disease. Mov Disord 1991;6:36e42.
[25] Guehl D, Cuny E, Benazzouz A, Rougier A, Tison F, Machado S, et al. Side-
effects of subthalamic stimulation in Parkinson’s disease: clinical evolution
and predictive factors. Eur J Neurol 2006;13:963e71.
[26] Klostermann F, Ehlen F, Vesper J, Nubel K, Gross M, Marzinzik F, et al. Effects
of subthalamic deep brain stimulation on dysarthrophonia in Parkinson’s
disease. J Neurol Neurosurg Psychiatry 2008;79:522e9.
[27] Houeto JL, Welter ML, Bejjani PB, Tezenas du Montcel S, Bonnet AM,
Mesnage V, et al. Subthalamic stimulation in Parkinson disease: Intraoperative
predictive factors. Arch Neurol 2003;60:690e4.
[28] Herzog J, Pinsker M, Wasner M, Steigerwald F, Wailke S, Deuschl G, et al.
Stimulation of subthalamic ﬁbre tracts reduces dyskinesias in STN-DBS. Mov
Disord 2007;22:679e84.
[29] Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW. Path-
ophysiology of levodopa-induced dyskinesias in Parkinson’s disease: prob-
lems with the current model. Ann Neurol 2000;47:S22e32. discussion
S32eS24.
[30] Foffani G, Ardolino G, Meda B, Egidi M, Rampini P, Caputo E, et al. Altered
subthalamo-pallidal synchronisation in parkinsonian dyskinesias. J Neurol
Neurosurg Psychiatry 2005;76:426e8.
[31] Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, et al. Pallidal versus
subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med
2011;362:2077e91.
[32] Bandini F, Primavera A, Pizzorno M, Cocito L. Using STN DBS and medication
reduction as a strategy to treat pathological gambling in Parkinson’s disease.
Parkinsonism Relat Disord 2007;13:369e71.
[33] Smeding HM, Goudriaan AE, Foncke EM, Schuurman PR, Speelman JD,
Schmand B. Pathological gambling after bilateral subthalamic nucleus stim-
ulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007;78:517e9.
S.-T. Tsai et al. / Tzu Chi Medical Journal 24 (2012) 65e7272[34] Ballanger B, van Eimeren T, Moro E, Lozano AM, Hamani C, Boulinguez P, et al.
Stimulation of the subthalamic nucleus and impulsivity: release your horses.
Ann Neurol 2009;66:817e24.
[35] Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, et al.
Chronic dopaminergic stimulation in Parkinson’s disease: from dyskinesias to
impulse control disorders. Lancet Neurol 2009;8:1140e9.[36] Calne SM, Kumar A. Young onset Parkinson’s disease. Practical
management of medical issues. Parkinsonism Relat Disord 2008;14:
133e42.
[37] Terao T, Takahashi H, Yokochi F, Taniguchi M, Okiyama R, Hamada I.
Hemorrhagic complication of stereotactic surgery in patients with movement
disorders. J Neurosurg 2003;98:1241e6.
